| |
A very small percentage of nonclinical lead assets move into the clinic. That’s why it is crucial to develop an optimized nonclinical strategy that leverages smart planning and design to de-risk critical early-stage milestones. It could mean the difference between success and failure. Read our guide to ensure your nonclinical program has the best chance to advance to Phase 1 – and beyond. 
|
|
Today’s Big NewsMay 6, 2024 |
|
Tuesday, May 14, 2024 | 9:30am ET / 6:30am PT This webinar dives into patient-derived organoids viewed as the gold standard in bridging the gap between the lab and the clinic. The oncology portfolio allows researchers to incorporate patient relevance at every stage of the drug development pipeline - from target discovery and hit identification to lead validation and optimization. Register now. 
|
|
| By Gabrielle Masson The Novo Nordisk Foundation, Wellcome and the Bill & Melinda Gates Foundation have inked a $300 million R&D initiative focused in part on infectious diseases and antimicrobial resistance. |
|
|
|
By Nick Paul Taylor GlycoMimetics CEO Harout Semerjian told investors in March that phase 3 blood cancer results could “fundamentally impact our company's trajectory.” And the CEO was absolutely right, just not in the way he hoped. |
By Max Bayer Italian pharma Chiesi is betting almost $500 million to jointly commercialize Gossamer's late-stage Winrevair rival. The asset is currently enrolling patients in a phase 3 study. |
Sponsored by MindMed Generalized anxiety disorder afflicts millions however, the latest treatment was approved in 2007. Now MindMed is advancing a new treatment paradigm. |
By Angus Liu Citi analyst Andrew Baum, after covering Pfizer for more than a decade, will join the Big Pharma company as chief strategy and innovation officer. In the role, he'll oversee the drugmaker's portfolio management and business development activities. |
By Gabrielle Masson,Max Bayer We really didn't want to have to create another Layoff Tracker this year. But here we are, launching the third annual iteration tracking biopharma layoffs. |
By Conor Hale The watch’s sensor and software marked the first digital health product to be qualified under the agency’s Medical Device Development Tools program. |
By Fraiser Kansteiner With plans to have at least 10 potentially registrational trials underway by the end of 2024, BioNTech is plotting the first wave of its market debut in oncology from 2026 onward. |
By Eric Sagonowsky Targeting a major pharmaceutical market in retinal diseases, EyePoint Pharmaceuticals has revealed that its lead candidate failed to meet its primary endpoint in a phase 2 trial. |
By Anastassia Gliadkovskaya The data set includes just over 1 million mother-child pairs collected from 30 health systems. Going back between five and 10 years, this makes it the largest mother-child EHR data set available today, according to the company. |
Fierce podcasts Don’t miss an episode |
| This week on "The Top Line," we're diving into the details of the spree of big-money biopharma deals in 2023 and examining what that means for this year. |
|
|---|
|
|
Whitepaper Precision collection of cell therapy source material doesn’t happen by chance. Our new whitepaper illuminates the science and strategies for successful apheresis. Sponsored by: Comprehensive Cell Solutions |
Whitepaper Learn how Specifica’s in vitro antibody discovery platform can deliver better antibodies than traditional immunization approaches. Sponsored by: Specifica, a Q2 Solutions company |
Whitepaper This paper defines “digital companions” in biopharma, explores their value from the patient & company perspectives, & outlines a process for successfully fielding a new digital companion. Presented by: Blue Matter, strategic consultants in the life sciences |
Whitepaper Explore the complex considerations of vaccine development for influenza and COVID-19, including the challenges posed by viral evolution and the importance of ongoing research in this paper by vaccine expert, Dr. Lisa Kierstead. Sponsored by: PPD®️ Laboratory Services |
eBook To make every rare disease trial count, we design patient-centric, relevant strategies for sponsors and caregivers to produce impactful results every time. Sponsored by: Emmes Company |
Whitepaper Discover the secrets behind successful patient engagement Sponsored by: ProofPilot |
Whitepaper Antibody biomarkers are redefining precision medicine, from diagnosing diseases earlier to stratifying patients – download your FREE white paper today! Sponsored by: Sengenics Corporation LLC |
Whitepaper The use of prefilled syringes to administer biotherapeutics is beginning to gain traction because they offer a range of stability, efficacy, and patient safety benefits. Download this white paper to learn how Lonza has developed a novel workflow to ensure confidence regarding functionality in PFS and autoinjectors. Presented by Lonza |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| |
|
